Cornedine J. de Gooijer

Author

Also Known As

C. Gooijer, C.J. De Gooijer, C.J. de Gooijer, Cornedine J de Gooijer, Cornedine J. De Gooijer, Cornedine J. Gooijer, Cornedine J. de Gooijer, Cornedine Jannette de Gooijer

Publications

517

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Erasmus MC Cancer Institute Zuyderland Medisch Centrum University Medical Center Groningen Radboud University Nijmegen

About

Cornedine J. de Gooijer is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	175
2	Health Sciences	2	2	88
3	Head And Neck Surgery	1	1	58
4	Otolaryngology	1	1	58
5	Pathology	1	1	17

Cornedine J. de Gooijer

Publications

300

Citations

H-Index

Page 1

	Year	Citations
T3‐T4 laryngeal cancer in The Netherlands Cancer Institute; 10‐year results of the consistent application of an organ‐preserving/‐sacrificing protocol Adriana J. Timmermans, Cornedine J. de Gooijer, Olga Hamming‐Vrieze, Head & Neck Surgical OncologyCancer ManagementTonsillectomyNetherlands Cancer InstituteSurgery	2014	58
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial Cornedine J. de Gooijer, Vincent van der Noort, Jos A. Stigt, The Lancet Respiratory Medicine First-line ChemotherapySwitch-maintenance GemcitabineMalignant DiseaseMedicineMalignant Mesothelioma	2021	47
Real life experience with nivolumab for the treatment of non-small cell lung carcinoma Robert D. Schouten, Mirte Muller, Cornedine J. de Gooijer, Lung Cancer OncologyHealth SciencesImmune Checkpoint InhibitorBronchial NeoplasmCancer Treatment	2017	41
Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program Luca Cantini, Robert A. Belderbos, Cornedine J. de Gooijer, Translational Lung Cancer Research	2020	40
Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma Daphne W. Dumoulin, Li-Anne H Douma, Maaike M. Hofman, Lung Cancer	2023	27
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response Floris Dammeijer, Cornedine J. de Gooijer, Mandy van Gulijk, EBioMedicine	2021	26
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC M. Jebbink, Adrianus J. de Langen, Kim Monkhorst, JTO Clinical and Research Reports	2023	21
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study Li-Anne H Douma, Ferry Lalezari, Vincent van der Noort, The Lancet Oncology Single-arm Phase 2Third-line PatientsMedicinePathologyPleural Effusion	2023	17
Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib René J. Boosman, Cornedine J. de Gooijer, Stefanie L. Groenland, Pharmaceutical Research Ritonavir-boosted ExposureOpen LabelPharmacologyKinase InhibitorsPharmacological Issue	2022	12
Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care Robert D. Schouten, Lucie Egberink, Mirte Muller, Translational Lung Cancer Research	2020	11

Page 1